Document is current
Any future updates will be listed below
-
Authors
Tiss, Amal
Michaelson, Nara M.
Russo, Andrew W.
Ramos-Torres, Karla M.
Sun, Yang
DaSilva, Nicole E.
Noel, Jacqueline M.
Liu, Fang
Gong, Kuang
Huang, Susie Y.
Popko, Brian
Baker, Suzanne
Klawiter, Eric C.
Brugarolas, Pedro https://orcid.org/0000-0002-7455-2743
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS114066)
University of Chicago (Innovation Fund Award from the Polsky Center for Innovation and Entrepreneurship, Innovation Fund Award from the Polsky Center for Innovation and Entrepreneurship)
Massachusetts General Hospital (Executive Committee on Research Physician Scientist Development Award, Translational Neuroscience Innovation/Anne B. Young Fellowship)
- License Information
-
More Information
Article History
Received: 8 April 2025
Accepted: 4 July 2025
First Online: 5 August 2025
Declarations
:
: Pedro Brugarolas and Brian Popko are named inventors on patents related to [18F]3F4AP owned by the University of Chicago. Dr. Brugarolas’ interests were reviewed and are managed by Massachusetts General Hospital (MGH) and Mass General Brigham in accordance with their conflict-of-interest policies. All other authors have no potential conflicts of interest to report.
: Studies in human research subjects were performed in line with the principles of the Declaration of Helsinki. Prior approval was granted by the Institutional Review Board (IRB) at the Massachusetts General Hospital (IRB# 2020P002459, PI: Brugarolas). The study was registered in ClinicalTrials.gov (NCT04699747, Sponsor: Massachusetts General Hospital, Responsible Party: P. Brugarolas). [18F]3F4AP was administered under an investigational new drug (IND) authorization from the U.S. Food and Drug Administration (FDA) (IND # 135,532, Sponsor: Brugarolas).
: Informed consent was obtained from all individual participants included in the study.
